Rakuten Medical, Inc. and LOTTE Biologics have announced a strategic contract manufacturing partnership designed to strengthen Rakuten Medical’s production capabilities for its innovative Alluminox photoimmunotherapy platform. The agreement, finalized at the J.P. Morgan Healthcare Conference in San Francisco, will help support the company’s global clinical programs and prepare for the future commercialization of its therapies, ensuring a stable supply of critical components.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Under the partnership, LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates. This will enable Rakuten Medical to meet growing demand from ongoing clinical trials and expanding adoption in treatment centers. By leveraging LOTTE Biologics’ specialized expertise, the collaboration aims to maintain high-quality standards while meeting international regulatory requirements.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
Rakuten Medical’s Alluminox technology targets solid tumors by combining antibodies that recognize cancer cells with light-activated agents. This approach allows for precise destruction of tumor cells while sparing surrounding healthy tissue. In Japan, the therapy is approved for recurrent head and neck cancer and has seen a steady increase in patient treatments, reflecting broader clinical adoption and year-over-year growth.
Globally, Phase 3 clinical trials are underway in the United States, Taiwan, and Japan, with plans to expand to Ukraine and Poland soon. Additionally, Rakuten Medical intends to begin Phase 1 trials in Japan for other solid tumors beyond head and neck cancer later this year. The rising clinical activity is driving a greater need for high-quality bioconjugates, which LOTTE Biologics is well-positioned to deliver.
LOTTE Biologics has been expanding its capabilities as a global contract development and manufacturing organization, particularly in monoclonal and multispecific antibodies, antibody-drug conjugates, and advanced bioconjugation services. The company will produce components for Rakuten Medical’s programs at its Syracuse Bio Campus facility in New York, utilizing advanced ADC production technologies to provide reliable manufacturing for global distribution. This partnership reinforces both companies’ commitment to supporting the development and commercialization of innovative oncology therapies worldwide.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
